NuCana (NASDAQ:NCNA) Trading Up 3.1% – Still a Buy?

NuCana PLC Sponsored ADR (NASDAQ:NCNA) shares were up 3.1% during trading on Tuesday . The stock traded as high as $2.1125 and last traded at $2.01. Approximately 24,723 shares traded hands during mid-day trading, a decline of 26% from the average daily volume of 33,347 shares. The stock had previously closed at $1.95.

Wall Street Analysts Forecast Growth

NCNA has been the subject of a number of recent analyst reports. Wall Street Zen upgraded shares of NuCana from a “sell” rating to a “hold” rating in a report on Saturday, November 22nd. Weiss Ratings reiterated a “sell (e+)” rating on shares of NuCana in a research note on Thursday, January 22nd. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Sell”.

NuCana Stock Up 2.1%

The firm has a market capitalization of $59,700.00, a price-to-earnings ratio of -0.01 and a beta of 1.69. The business has a 50-day moving average of $2.66 and a two-hundred day moving average of $3.51.

Institutional Trading of NuCana

An institutional investor recently raised its position in NuCana stock. FNY Investment Advisers LLC increased its position in NuCana PLC Sponsored ADR (NASDAQ:NCNA) by 210.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 10,000 shares of the company’s stock after purchasing an additional 6,774 shares during the quarter. FNY Investment Advisers LLC owned approximately 33.33% of NuCana worth $36,000 at the end of the most recent quarter. 44.00% of the stock is currently owned by hedge funds and other institutional investors.

About NuCana

NuCana plc, headquartered in Edinburgh, Scotland, is a clinical-stage biopharmaceutical company focused on developing novel anti-cancer therapies. The company leverages its proprietary ProTide platform to deliver enhanced nucleoside analogues designed to overcome resistance mechanisms commonly encountered in standard chemotherapy regimens. NuCana’s research and development efforts are aimed at improving safety and efficacy profiles for patients with a range of solid tumor indications.

At the core of NuCana’s pipeline is NUC-3373, a next-generation fluoropyrimidine analogue engineered to bypass degradation pathways and achieve more consistent intracellular exposure.